Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in association with endocrine therapy (ET). However, even if t...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2023-03-01
Schriftenreihe:	Diagnostics
Schlagworte:	CDK4/6 inhibitors advanced/metastatic breast cancer biomarkers of response progression on CDK4/6 inhibitors resistance mechanisms endocrine therapy
Online-Zugang:	https://www.mdpi.com/2075-4418/13/5/987
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!